

PRESS RELEASE
Uppsala
January 9, 2006

Q-Med launches a new lip enhancement treatment

RESTYLANE Lipp is the latest advance from this trusted family of treatments, a unique formulation specifically designed for successful lip enhancement. Like all of the RESTYLANE treatments, RESTYLANE Lipp is 'tissue-tailored' and formulated to work in harmony with the natural anatomy of the lip.

Based on patented NASHA* technology, RESTYLANE Lipp, which is biologically degradable, has a "cohesive yet dynamic" gel configuration and is structured to retain its shape, despite the complex movements and rich vasculature associated with the lip area.

RESTYLANE Lipp is an innovative development in the RESTYLANE range, which are internationally leading products for treatment of wrinkles and for lip enhancement. With 10 years' experience, and 4 million treatments behind it, RESTYLANE delivers proven efficacy and well-documented safety.

*) NASHA, Non-Animal Hyaluronic Acid

Queries should be addressed to:
Anne Rhenman,
Director Investor Relations & Corporate Communications
Tel: +46 (0) 70 974 90 15

Charles Weatherstone,
International Brand Team Leader
Private Healthcare Strategic Marketing
Phone: +44 (0) 7739 25 48 42

NASHA, DUROLANE, ZUIDEX, IMPLACER, DEFLUX and all the products within the RESTYLANE family are trademarks that belong to Q-Med.

In the US, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.

Q-Med AB (publ)
Seminariegatan 21, SE-752 28 Uppsala, Sweden
Corporate identity number 556258-6882
Tel: +46(0) 18-474 90 00
Fax: +46(0) 18-474 90 01
info@q-med.com
www.q-med.com

Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces and markets medical implants. All products are based on the company's patented NASHA technology - Non-Animal Stabilized Hyaluronic Acid. The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. RESTYLANE is sold in over 70 countries and has been approved in the USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the hip and knee joints, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (a malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Q-Med today has approximately 550 employees, with approximately 350 at the company's production facility and head office in Uppsala. The Q-Med share is listed on the O-list of Stockholmsborsen.